Overview

Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury

Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.
Phase:
Phase 2
Details
Lead Sponsor:
Rehabilitation Hospital of Indiana
Collaborator:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride